Study The Safety And Effectiveness Of Doxofylline In The Treatment Of Dyspnea Associated With Ticagrelor

BackgroundTicagrelor is a selective P2Y12 receptor antagonist,a new antiplatelet drug,widely be used in patients with coronary heart disease.PLATO study shows that ticagrelor is more effective in preventing myocardial infarction and death than clopidogrel in acute coronary syndrome,and does not increase the overall risk of severe bleeding.With the wide application of ticagrelor in clinic,more and more people pay close attention to the dyspnea.In view of the high incidence of dyspnea associated with ticagrelor,its mechanism and treatment method is very few,and after stoppinf the use of the medicine,the clinical benefit is reduced,and easily causing misdiagnosed in clinic,resulting in a waste of resources,so it is necessary to find an effective drug treatment method.ObjectiveTo Study the safety and effectiveness of doxofylline in the treatment of CHD patients with dyspnea associated with ticagrelor.MethodsSelected 200 patients with coronary heart disease that were diagnosed asdyspnea associated with ticagrelor from February 2015 to July 2016 in the first Affiliated Hospital of Zhengzhou University.They were divided into two group randomly:intervention group and control group.The intervention group took doxofylline(trade name: An Sai Ma,specification: 200 mg per piece)one piece two times a day for 5 days;The control group took placebo.After a day of treatment,record the total remission rate of the two groups,the platelet aggregation rate before and after 5 days of treatment,and cardiovascular mortality,myocardial infarction,stroke,bleeding and other adverse cardiovascular and cerebrovascular events for 6months.Result1.After one day of application of doxofylline,the total remission rate of the two groups intervention group was 93.0 percent,the control group was 62.8 percent.The two groups remission rate of dyspnea was no difference(P<0.05).2.Before the application of doxofylline,the rate of platelet aggregation of the intervention group was 35.53 + 5.1 percent,the control group was 35.16+4.6 percent,two groups platelet aggregation rate showed no significant difference(P>0.05).3.After taking doxofylline five days later,the rate of platelet aggregation of the intervention group was 26.48 + 4.3percent,the control group was 25.98 + 4.7 percent,two groups platelet aggregation rate showed no significant difference(P>0.05).4.There was no significant difference after six months in the incidence of adverse cardiovascular events such as cardiac death,myocardial infarction,stroke and bleeding in the two groups(P>0.05).ConclusionDoxofylline was effective in the treatment of ticagrelor related dyspnea,and does not affect the effect of ticagrelor on platelet aggregation.